PF-Atlas › Clinical Trials › NCT01759511
Long-Term Safety Study of GS-6624 in Adults With Idiopathic Pulmonary Fibrosis
Simtuzumab · Phase 2
Registry ID
NCT01759511
Phase
Phase 2
Status
Terminated
Drug / intervention
Simtuzumab
Sponsor
Gilead Sciences
Start
2012-10-18
Enrollment
34
Locations
6
About this trial
The primary objective of this study is to evaluate the long term safety and tolerability of simtuzumab (GS-6624) in participants with idiopathic pulmonary fibrosis (IPF) who had previously participated in Gilead clinical trial AB0024-201.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT01759511 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.